ARA-290: erythropoietin's repair signal, minus the red cells

ARA-290, also called cibinetide, is a short synthetic peptide copied from one specific stretch of the erythropoietin (EPO) protein. EPO is best known as the hormone that drives red blood cell production, yet a long line of laboratory work established that the same protein also guards stressed and injured tissue through a separate signalling route. ARA-290 was engineered to keep that tissue-protective activity while dropping the red-cell-stimulating activity, giving researchers a cleaner way to probe protection on its own.

The design starts from the three-dimensional shape of EPO. Native EPO folds into four helices, and the outer face of one of them, helix B, sits away from the region that switches on red blood cell production. Researchers found that a compact peptide matching that helix-B surface could still engage the protective receptor without touching the part responsible for erythropoiesis. ARA-290 is the refined 11-residue version of that idea, small enough to synthesise reliably and stable enough to work with at the bench.

The background here is worth setting out plainly. For years the tissue-protective effects seen with EPO in laboratory models were hard to separate from its main job. Raising EPO enough to protect nerve or vascular tissue also lifted red cell mass and blood viscosity, which muddied interpretation. Splitting the two activities at the molecular level, first by pinpointing the receptor responsible for protection and then by building peptides that hit only that receptor, is what made a compound like ARA-290 possible.

What the molecule is

ARA-290 is an 11-amino-acid peptide. Its first residue is a cyclised pyroglutamate, meaning the leading glutamine has looped back on itself to form a ring. That detail matters for anyone expecting a tidy one-letter sequence string: because the N-terminal residue is modified rather than a standard free amino acid, the peptide does not reduce to a clean single-letter code. The confirmed identifiers below (molecular formula, mass, and CAS number) are the reliable way to reference the exact molecule, and they are what a lab should check batch identity against.

The innate repair receptor

The target of ARA-290 is the innate repair receptor, often shortened to IRR. It is not a single protein but a paired complex that brings together the EPO receptor and the beta-common receptor, also labelled CD131. Full-strength EPO signals mainly through a homodimer of two EPO-receptor chains, and that homodimer is what pushes red blood cell output. The IRR is a different arrangement of subunits, and it is the arrangement linked to protection of nerve, vascular, and other tissue under stress.

Selectivity is the whole point. By binding the IRR while largely ignoring the erythropoietic homodimer, ARA-290 lets researchers study the protective arm of EPO biology without the confound of rising red cell counts. Tissue that is inflamed or metabolically strained tends to upregulate the beta-common receptor, so the peptide's activity concentrates where the repair machinery is already switched on rather than spreading across the whole body. That local bias is one reason the compound is attractive as a mechanistic probe.

What the research shows

Two foundational reports from the Brines group map this out. The 2004 PNAS paper showed that EPO's tissue protection runs through a receptor that includes the common beta subunit, separating protection from red cell production at the receptor level. The 2008 PNAS paper went further, deriving small nonerythropoietic peptides directly from the folded structure of EPO. Those helix-B surface peptides are the direct ancestors of ARA-290, and in laboratory models they retained protective signalling while shedding the erythropoietic effect.

Later laboratory and preclinical work has examined ARA-290 in models of peripheral nerve damage, ischemic and inflammatory stress, and metabolic strain, where the peptide has been reported to lower markers of inflammation and support cell survival. This body of work is investigational: it establishes a mechanism and a set of model results, not a settled account of what the peptide does across every tissue. Read alongside the two founding papers, it is a coherent picture of a selective repair-receptor agonist, still being worked out.

Why the selectivity is useful at the bench

For a research setting, a selective IRR agonist is a clean tool. It isolates one signalling pathway, it is a defined small peptide rather than a full glycoprotein, and its confirmed mass and formula make batch identity straightforward to verify. Those properties are why ARA-290 turns up repeatedly in mechanistic studies of the EPO protective pathway, and why it is often used as a reference point when newer helix-B mimetics are characterised.

Verified molecule

• Name: ARA-290 (cibinetide)
• Molecular formula: C51H84N16O21
• Molecular weight: 1257.3 g/mol
• CAS number: 1208243-50-8
• Class: 11-residue helix-B surface peptide derived from erythropoietin, a selective agonist of the innate repair receptor (EPO receptor plus beta-common/CD131)
• N-terminus: cyclised pyroglutamate, so there is no clean one-letter sequence code

Common questions

Is ARA-290 the same thing as erythropoietin?

No. ARA-290 is an 11-residue peptide modelled on just the helix-B surface of the much larger EPO protein. It shares a protective signalling route with EPO but is a distinct, smaller molecule, and it does not carry the sugar chains or the red-cell-stimulating shape of the parent hormone.

Why does it not raise red blood cell counts in laboratory models?

Red cell production is driven by EPO binding a homodimer of two EPO-receptor chains. ARA-290 is selective for the innate repair receptor, the EPO-receptor plus beta-common (CD131) complex, so in reported model systems it engages the protective pathway while largely bypassing the homodimer that controls erythropoiesis.

What does the N-terminal pyroglutamate mean for the sequence?

The first residue is cyclised, so the peptide does not collapse into a clean one-letter sequence string. When you need to confirm identity, rely on the molecular formula, molecular weight, and CAS number rather than a single-letter code.

For laboratory research use only. Not for human or veterinary use.

References

1. Brines M, et al. Erythropoietin mediates tissue protection through erythropoietin and the common beta-subunit heteroreceptor. Proceedings of the National Academy of Sciences (PNAS), 2004; 101(41): 14907-14912.
2. Brines M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences (PNAS), 2008; 105(31): 10925-10930.